Toxicity of high-dose intravitreal adalimumab (Humira) in the rabbit

Journal of Ocular Pharmacology and Therapeutics

Volumn 27, Issue 4, 2011, Pages 327-331

  Manzano, Roberta P A ^a,b   Peyman, Gholam A ^c   Carvounis, Petros E ^d   Damico, Francisco Max ^a   Aguiar, Renata Genaro ^a   Ioshimoto, Gabriela L ^a   Ventura, Dora Fix ^a   Cursino, Sylvia T ^b   Takahashi, Walter ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Santa Casa of São Paulo ^*  (Brazil)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d CULLEN EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR EYE CHAMBER; ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; ELECTRORETINOGRAM; ELECTRORETINOGRAPHY; EXPERIMENTAL RABBIT; EYE INFLAMMATION; EYE TOXICITY; HISTOPATHOLOGY; NIGHT VISION; NONHUMAN; OPHTHALMOSCOPY; PHOTOPIC VISION; SLIT LAMP;

ANIMALS; ANTERIOR CHAMBER; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRORETINOGRAPHY; FEMALE; INFLAMMATION; INTRAVITREAL INJECTIONS; MICROSCOPY; OPHTHALMOSCOPY; RABBITS; TIME FACTORS;

EID: 79961183899     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2010.0174     Document Type: Article

References (21)

1. Weinblatt, M.E., Keystone, E.C., Furst, D.E., Moreland, L.W., Weisman, M.H., Birbara, C.A., et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum. 48:35-45, 2003. (Pubitemid 36091645)
2. Weisman, M.H., Moreland, L.W., Furst, D.E., Weinblatt, M.E., Keystone, E.C., Paulus, H.E., et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human antitumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study. Clin. Ther. 25:1700-1721, 2003. (Pubitemid 36801943)
3. Wiedmann, M.W., Mossner, J., Baerwald, C., and Pierer, M. TNF alpha inhibition as treatment modality for certain rheumatologic and gastrointestinal diseases. Endocr. Metab. Immune Disord. Drug Targets 9:295-314, 2009.
4. Mpofu, S., Fatima, F., and Moots, R.J. Anti-TNF-alpha therapies: They are all the same (aren't they?). Rheumatology (Oxford) 44:271-273, 2005. (Pubitemid 40361279)
5. Kahn, P., Weiss, M., Imundo, L.F., and Levy, D.M. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 113:860-864 e2, 2006.
6. Vazquez-Cobian, L.B., Flynn, T., and Lehman, T.J. Adalimumab therapy for childhood uveitis. J. Pediatr. 149:572-575, 2006. (Pubitemid 44468085)
7. Biester, S., Deuter, C., Michels, H., Haefner, R., Kuemmerle- Deschner, J., Doycheva, D., et al. Adalimumab in the therapy of uveitis in childhood. Br. J. Ophthalmol. 91:319-324, 2007. (Pubitemid 46586527)
8. Lichtlen, P., Lam, T.T., Nork, T.M., Streit, T., and Urech, D.M. Relative contribution of VEGF and TNF-alpha in the cynomolgus laser-induced CNV model: Comparing the efficacy of bevacizumab, adalimumab, and ESBA105. Invest. Ophthalmol. Vis. Sci. 51:4738-4745, 2010.
9. Markomichelakis, N.N., Theodossiadis, P.G., and Sfikakis, P.P. Regression of neovascular age-related macular degeneration following infliximab therapy. Am. J. Ophthalmol. 139:537-540, 2005. (Pubitemid 40379086)
10. Manzano, R.P., Peyman, G.A., Carvounis, P.E., Kivilcim, M., Khan, P., Chevez-Barrios, P., et al. Ocular toxicity of intravitreous adalimumab (Humira) in the rabbit. Graefes Arch. Clin. Exp. Ophthalmol. 246:907-911, 2008.
11. Tsilimbaris, M., Diakonis, V.F., Naoumidi, I., Charisis, S., Kritikos, I., Chatzithanasis, G., et al. Evaluation of potential retinal toxicity of adalimumab (Humira). Graefes Arch. Clin. Exp. Ophthalmol. 247:1119-1125, 2009.
12. Androudi, S., Tsironi, E., Kalogeropoulos, C., Theodoridou, A., and Brazitikos, P. Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmology 117:1612- 1616, 2010.
13. Kim, H.D., Park, J.Y., and Ohn, Y.H. Clinical applications of photopic negative response (PhNR) for the treatment of glaucoma and diabetic retinopathy. Korean J. Ophthalmol. 24:89-95, 2010.
14. Machida, S., Gotoh, Y., Tanaka, M., and Tazawa, Y. Predominant loss of the photopic negative response in central retinal artery occlusion. Am. J. Ophthalmol. 137:938-940, 2004. (Pubitemid 38582052)
15. Drasdo, N., Aldebasi, Y.H., Chiti, Z., Mortlock, K.E., Morgan, J.E., and North, R.V. The s-cone PHNR and pattern ERG in primary open angle glaucoma. Invest. Ophthalmol. Vis. Sci. 42:1266-1272, 2001. (Pubitemid 32381968)
16. Viswanathan, S., Frishman, L.J., Robson, J.G., and Walters, J.W. The photopic negative response of the flash electroretinogram in primary open angle glaucoma. Invest. Ophthalmol. Vis. Sci. 42:514-522, 2001. (Pubitemid 32121488)
17. Dick, H.B., Augustin, A.J., Pakula, T., and Pfeiffer, N. Endotoxins in ophthalmic viscosurgical devices. Eur. J. Ophthalmol. 13:176-184, 2003. (Pubitemid 36433862)
18. Park, H.S., and Kim, M.S. The inflammatory potential of surgical glove lubricants: Biosorb, Keoflo, calcium carbonate and Hydrocote after intravitreal injection. Korean J. Ophthalmol. 11:51-59, 1997.
19. Ness, T., Feltgen, N., Agostini, H., Bohringer, D., and Lubrich, B. Toxic vitreitis outbreak after intravitreal injection. Retina 30:332-338, 2010.
20. Giganti, M., Beer, P.M., Lemanski, N., Hartman, C., Schartman, J., and Falk, N. Adverse events after intravitreal infliximab (Remicade). Retina 30:71-80, 2010.
21. Theodossiadis, P.G., Liarakos, V.S., Sfikakis, P.P., Vergados, I.A., and Theodossiadis, G.P. Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration. Am. J. Ophthalmol. 147:825-830, 2009.